Q-omics provides the consensus-scored MYL12A profile across patient tissues and cancer cell-line models. MYL12A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MYL12A is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, MYL12A RNA expression shows 18,596 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where MYL12A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYL12A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYL12A survival associations across molecular data types. MYL12A RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYL12A RNA expression–survival associations across cancer types. High MYL12A expression shows unfavorable associations in ACC, HNSC, LGG, UVM and MESO, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MYL12A RNA expression.
This table summarizes MYL12A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MYL12A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYL12A shows lower tumor expression in KICH, LUSC and LUAD and higher tumor expression in LIHC, HNSC and CHOL. The KICH box plot shows higher MYL12A RNA expression in normal versus tumor tissue (log2 FC = −1.915, t-test p < 0.001).
This table shows molecular features associated with MYL12A in patient tissues and cancer cell lines. In patient samples, MYL12A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYL12A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
